The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Roche is finding new ways to keep its oncology and rheumatoid arthritis blockbuster Rituximab/MabThera (rituximab) a big seller, despite the imminent arrival of biosimilar competition in Europe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback